Molecular diagnostics offers a powerful new tool to help oncologists and pathologists study the genetic causes of cancer as well as the potential of targeted therapies, opening the door to the promising potential of personalized medicine. For cancer researchers conducting mechanism studies, biomarker screening and validation, and therapeutic target discovery, Novogene’s NovoPMTM cancer panel is a cost-effective technology that enriches specific regions or targeted genes through probe hybridization. More affordable than whole-genome and whole-exome sequencing to identify variants underlying the pathogenesis of cancer, NovoPMTM cancer panel is available for both tissue and liquid biopsy. As of August 2016, Novogene has applied its NovoPMTM cancer panel to 3,848 tumor tissue samples and to 2,122 liquid biopsy samples.
Novogene NovoPMTM cancer panel for solid tumors is a comprehensive genetic analysis that simultaneously sequences the coding region of 483 cancer-related genes and selected introns from 19 genes. Custom panels are also available based on your specific request. The panel covers most major cancers (lung, colon, esophageal, gastric, breast, etc.), examining selected genes based on National Comprehensive Cancer Network (NCCN) guidelines for your basic research in support of personalized medicine.
Non-invasive Liquid Biopsy
In most cases, a biopsy of tumor tissue is costly, painful and potentially risky for patients, especially those with late-stage cancer. Non-invasive liquid biopsy of circulating tumor DNA (ctDNA) in plasma can provide molecular information similar to that derived from invasive tumor biopsies at less cost and with less risk. Novogene is accepting plasma and ctDNA samples from cancer researchers interested in non-invasive liquid biopsy testing studies. As with our tissue biopsy test, our liquid biopsy panel sequences the coding region of 483 cancer-related genes and selected introns from 19 genes. Custom panels are also available upon request.
The Novogene Advantage
- Competitive Price. Most cost-effective service for cancer studies, especially for ultra-deep sequencing coverage needs.
- Flexibility. Plasma, ctDNA, DNA from tissue, and FFPE samples are acceptable.
- Advanced Technology. State-of-the-art target enrichment kit from Agilent and advanced Illumina HiSeq sequencing platform to provide the most reliable data output.
- Professional Bioinformatics Team. Hundreds of bioinformaticians with thousands of completed projects provide the most extensive analysis and expert interpretation available.
- 180-280 bp insertion DNA library
- HiSeq platform, paired-end 150 bp
Data Quality Guarantee
- Q30 ≥ 80%
- DNA amount quantified by Qubit 2.0
- For plasma sample: ≥ 5 ml
- For ctDNA sample: ≥ 400 ng (for two libraries preparation); Minimum: 200 ng
- For DNA sample: ≥ 2.0 μg (for two libraries preparation); Minimum: 500 ng
- For FFPE sample: ≥ 3.0 μg (for two libraries preparation); Minimum:1 μg
- DNA concentration: ≥ 20 ng/μL
- Total volume: ≥ 10 μL
- Purity: OD260/280 = 1.8-2.0 without degradation or RNA contamination
Turnaround Time (for RUO outside of China)
- Standard Panel: Delivery within 4-6 weeks from sample verification
- Custom Panel: Custom Probe time plus 4-6 weeks after sample verification
Recommended Sequencing Depth
- For tissue biopsy, effective average sequencing depth > 200×.
- For ctDNA samples or plasma samples, effective average sequencing depth > 500×.
Seeking potential therapeutic options, a breast cancer patient in China underwent a biopsy using our NovoPM cancer panel. As a result, we helped the patient’s physician to develop a plan for personalized therapy, leading to a promising outcome.
|Age||Cancer Type||Sample Type|
|53||Triple-negative breast cancer||Tissue Biopsy|
|HRAS point mutation (exon2 c.G37C:p.G13R)|
|BRAD1 Del (exon2 c.784_804del:p.262_268del)|
|1. HRAS belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. It is a key factor of EGFR signaling. Because of sustained activation of HRAs genes, the signal pathway will not be controlled by EGFR, which leads to bad sensitivity of EGFR mAbs and EGFR TKIs drugs.|
|2. BARD1 gene located in 2p34-35 is a tumor suppressor gene. Encoded BRAD1 protein combines with BRCA1 to form stable heterodimers thereby inhibiting tumor cell formation; at the same time, BARD1 is also independent from TP53 dependent apoptosis induction process mediated by BRCA1. BARD1 has E3 ubiquitin ligase activity, which helps biotinylated target protein degradation by the proteasome.|
|a. The clinical therapy for HRAS p.G13R mutation in breast cancer is unknown. However, HRAS p.G13R mutations of thyroid cancer might be more sensitive to MEK inhibitor Trametinib, when it combines with radioactive iodine therapy. Therefore we recommend Trametinib, which is a FDA-approved drug for Melanoma, and it could be a potential therapy.|
|b. Clinical therapy for BRAD1 mutation in breast cancer is unknown.|